Genextra

Their mission is to identify innovative research in life science and to develop novel therapies and tools by creating successful business initiatives in a sustained and long term way. Genextra's holding structure is designed to increase the probability of success of business initiatives that become part of the Group by providing specialist management as well as financial support to a new company vehicle or an existing young start-up. Genextra was created in 2004 by a group of prominent Italian entrepreneurs and financial institutions in partnership with leading scientists from the European Institute of Oncology (IEO). To date, Genextra has raised over €116 million and represents one of very few examples in Italy of private capital invested for the benefit of research and innovation.

Paolo Fundaro

CFO

7 past transactions

InnovHeart

Series C in 2022
InnovHeart is a medical equipment manufacturing company. They develop transcatheter mitral valve replacement systems. They bring patients a novel therapeutic system suitable to replace incompetent Mitral Valves based on a safe, effective, and easy-to-use transcatheter technology.

InnovHeart

Series B in 2020
InnovHeart is a medical equipment manufacturing company. They develop transcatheter mitral valve replacement systems. They bring patients a novel therapeutic system suitable to replace incompetent Mitral Valves based on a safe, effective, and easy-to-use transcatheter technology.

Erydel

Series B in 2018
Based in Urbino, EryDel has developed and patented a technology for drug delivery of pharmacological agents through erythrocytes (red blood cells). This process allow to easily load red blood cells with drugs, proteins, contrasting agents for diagnostic purposes, nanoparticles etc. that can be progressively released into the patient body thus allowing an increased efficacy of the therapy and a reduction of collateral effects. The benefit is extremely significant particularly for chronic pathologies that requires continuous daily treatments for patients which could be substituted by monthly transfusion of blood loaded with specific therapeutic agents. Currently, the solution has been tested by several patients for the treatment of Inflammatory Bowel Diseases (IBDs) such as ulcer colitis and Crohn disease. The company can provide a complete support for the drug delivery process including a specific device for the erythrocytes loading ("Red Cell Loader"), and disposable kits.

Intercept Pharmaceuticals

Series C in 2012
Intercept Pharmaceuticals is a biopharmaceutical company, that engages in discovering and developing small molecule drugs and therapeutics for the treatment of chronic fibrotic and metabolic diseases. It offers INT-747, an FXR modulating agent that treats patients with chronic autoimmune liver diseases. The company's drug development programs also focus on modulating bile acid receptors, and amelioration of metabolic and hepatic functions in chronic liver diseases

Intercept Pharmaceuticals

Series B in 2010
Intercept Pharmaceuticals is a biopharmaceutical company, that engages in discovering and developing small molecule drugs and therapeutics for the treatment of chronic fibrotic and metabolic diseases. It offers INT-747, an FXR modulating agent that treats patients with chronic autoimmune liver diseases. The company's drug development programs also focus on modulating bile acid receptors, and amelioration of metabolic and hepatic functions in chronic liver diseases

Intercept Pharmaceuticals

Series A in 2008
Intercept Pharmaceuticals is a biopharmaceutical company, that engages in discovering and developing small molecule drugs and therapeutics for the treatment of chronic fibrotic and metabolic diseases. It offers INT-747, an FXR modulating agent that treats patients with chronic autoimmune liver diseases. The company's drug development programs also focus on modulating bile acid receptors, and amelioration of metabolic and hepatic functions in chronic liver diseases

Intercept Pharmaceuticals

Venture Round in 2006
Intercept Pharmaceuticals is a biopharmaceutical company, that engages in discovering and developing small molecule drugs and therapeutics for the treatment of chronic fibrotic and metabolic diseases. It offers INT-747, an FXR modulating agent that treats patients with chronic autoimmune liver diseases. The company's drug development programs also focus on modulating bile acid receptors, and amelioration of metabolic and hepatic functions in chronic liver diseases
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.